The Board

Andrew Carter
Chair, BioMelbourne Network
Managing Director, Commercial Eyes

Maureen O'Keefe
Deputy Chair, BioMelbourne Network
CEO, Australian College of Optometry/National Vision Research Institute

Peter Lewis AM
Secretary, BioMelbourne Network
Director, Hydrix Pty Ltd

Nigel Baade
Treasurer, BioMelbourne Network
CFO and Company Secretary, Starpharma Pty Ltd

Dr Phil Kearney
Director, Business Development & Licensing, Merck Sharp & Dohme Aust.

Dr Lorna Meldrum
Vice President, Commercial Operations, Asia Pacific, Seqirus

Alun Needham
Director, KPMG

Retired Board Directors:

Joe Baini
Dr Ashley Bates
Andrew Macdonald

The Team

Dr Krystal Evans
Chief Executive Officer

Andie Beattie
Communications Officer

Vicky Jones
Membership Engagement Manager

Nicole Pitcher
Office Manager

Kristy Anderson
Events Assistant

Braden Pitcher
Marketing & Graphic Design Assistant

Contact Us

Phone Number
+61 3 9667 8181

Website
www.biomelbourne.org

Email
info@biomelbourne.org

Twitter
@biomelb

LinkedIn
BioMelbourne Network Group

Address
Milton House
Level 2, 25 Flinders Lane
Melbourne, Victoria
Australia, 3000
BioMelbourne Network (the Network) is an industry-led membership association for organisations engaged in biotechnology, medical technology, pharmaceuticals and health innovation in the state of Victoria.

Our role is to foster links between companies, research organisations, financial markets, professional services and government. This creates an environment for greater collaboration and prosperity.

With 184 member organisations, BioMelbourne Network plays a critical role in connecting health, research and industry capabilities and supporting the growth of Melbourne’s innovation economy.

The Network’s focus is local and our reach is global. The ultimate success of our members is built on a strong foundation of research and development, and a globally competitive innovation ecosystem here in the state of Victoria.

Melbourne is the city that anchors Australia’s health innovation system.

Melbourne’s world leading healthcare capabilities and unique research infrastructure makes our city the anchor for Australian health innovation.

Our membership highlights Melbourne’s unparalleled density of activity in biotechnology, medical technology, pharmaceuticals, digital health, advanced manufacturing, research, healthcare and enabling professional and scientific services.

The global market opportunity for the majority of our members is the healthcare sector. Innovation in healthcare technology is creating new Melbourne-based jobs, new growth and new industries for future economic prosperity.

The collaborative approach to health innovation adopted by our members facilitates their competitiveness in the global healthcare market.
Cities are innovation hubs that bring people and ideas together.

Melbourne is Australia’s fastest growing city and, in the not too distant future, will be Australia’s largest city. As a global innovation city, Melbourne draws together talented people, new technologies, world leading infrastructure, high calibre healthcare systems and financial markets.

Place is important for innovation and as a connected collaborative city, Melbourne has a style of doing business that draws on networks to drive innovation.

The Network provides a key competitive advantage for Melbourne’s future by connecting capabilities within the city, across Victoria, around Australia, and linking them into the global healthcare industry.

Melbourne is a city where talented, passionate people live and work.

Melbourne has been voted the most liveable city in the world for the 6th year in a row and is a place that many highly educated, talented people want to call home.

Access to human capital is a driver of global business success. The best technology in the world won’t make it to market without the right team around it. Our sector is powered by passionate people who develop the devices, diagnostics, drugs and digital tools that make a difference to peoples’ lives.

BioMelbourne Network supports human capital development to build Melbourne’s competitive advantage in attracting, training and retaining talented people. This returns social capital into the economy by growing businesses that create satisfying and rewarding careers for people living in Melbourne.

“Being a BioMelbourne Network Member has been incredibly valuable for us as a start-up... BioMelbourne has been fantastic in providing us with opportunities... Being surrounded by like minded people is critical when trying to achieve something that hasn’t been done before.”

Jacqueline Savage
Founder and Director of MedCorp Technologies
Our Message

a word from the Chair and the CEO

Since 2001 BioMelbourne Network has held a distinctive place in the Victorian life science ecosystem. Now in its 16th year, the association has a membership of over 180 organisations and is unique in terms of industry reach and membership representation.

BioMelbourne Network’s strength is built on recognising the convergence of biotechnology, medical technology and pharmaceuticals and drawing together leaders from across the health innovation sector, public and private industry, research institutes, financial markets, healthcare providers and government.

Connecting people from the various facets of the sector stimulates the creation of collaborative opportunities. This ultimately drives prosperity and delivers life changing technologies to people across the world.

Our Sector

The biotechnology, medical technology and pharmaceutical sector is a key element of the current and future economy of Melbourne, Victoria and the nation. As such, it was particularly encouraging this past year to see the State and Federal Governments recognise the importance of our sector and identify “Medical Technologies and Pharmaceuticals” as a high priority strategic growth sector for the future.

Member Engagement

The dynamic, high calibre gathering of industry professionals, combined with international speakers and access to industry intelligence, reinforces the Network’s position as the leading state-based forum for industry engagement in the health innovation sector.

Events

Creating regular opportunities for our members to connect with each other and with sector intelligence is a key area of focus for the BioMelbourne Network.

During the year the association delivered a record 49 events. An important element of these events has been the opportunity to showcase 131 speakers drawn from our membership, whilst also featuring other local and national experts and 15 international speakers.

As well as providing regular forums that strengthen existing business relationships within the sector, our events create many opportunities to make new industry contacts.

It is particularly encouraging to report that over 400 people attended their first BioMelbourne Network event during the year.

In addition to running formal events, the Network has facilitated hundreds of member connections, met 1-on-1 with members to discuss their challenges and future activities, and opened our doors - literally and virtually - to support our members.
Promoting Diversity

The Network is committed to enhancing gender diversity and the representation of women in the sector. In FY2016, 30% of speakers at our events were women, which is up from 23% in FY15. The annual BioMelbourne Network Women in Leadership Awards recognise women who have made outstanding contributions to the sector and in 2016 we were delighted to recognise Dr Jackie Fairley (Starpharma), Prof Sally MacArthur (Swinburne University of Technology) and Jacqueline Savage (Medcorp Technologies) with awards.

Industry Working Groups

As a new initiative this year, the Network established two working groups to reflect key areas of member interest; the Clinical Industry Working Group and the Industry:Academia Working Group. Both have been key intelligence sharing and activity driven groups, driven by the interests and expertise of members. Of particular note has been the work of the respective groups in engaging with government and providing input into the Network’s advocacy agenda. The groups have contributed to Federal Government submissions, met with State Government representatives and provided input into the strategies and priorities that shape our sector.

We thank each member of the working groups for their contribution and encourage staff of all member organisations to get involved with these and other working groups we have planned.

Communications

In March 2016 BioMelbourne Network welcomed Andie Beattie to take on a newly created role of Communications Officer.

Andie has worked for numerous media organisations in Melbourne and overseas. This experience incorporated marketing, public relations and conference production. Andie has also worked for a public relations consultancy supporting a UK member association with their multi-channel stakeholder relations program. In her role as Communications Officer for the Network, Andie is able to incorporate her lifelong interest and tertiary education in science with her communications experience.

In Q1 of 2016, the Network launched a new-look website. Encompassing a fresher and more modern look, the new website allows for online booking and payment for events, integration with the CRM as well as easier user navigation and back-end curation of information. Throughout the year various additional improvements have been made and we foresee that the site will continue to evolve to maximise our capacity to digitally engage with all our stakeholders.

Feedback from our members regarding the new website has been very positive as we have added new pages that provide members with additional communication opportunities as well as providing key sector information for international visitors to the site.

June 2016 saw a streamlining in our member communications with the fortnightly newsletter “Insider” provided to members only and an alternate fortnightly “In the Loop” mail-out to our wider sector contacts. These communications alert members and non-members to our activities, opportunities for grants and funding, news, jobs and events and are seen as a valuable tool for keeping the membership up-to-date with sector happenings.

Systems Improvement

During the year the association made a considerable investment in our internal systems, particularly with regard to adopting online and digital business tools.

We upgraded our financial system by moving to a cloud based accounting provider (Xero), modernised our membership management software (Zoho CRM) and made improvements to our business banking and payment systems.

This investment has delivered immediate benefit, improving how we engage with members, run events and increasing the efficiency of our operational activities.

Advocacy

Over the year the Network has represented members in a broad range of government forums. Some examples include high level strategic input into the:

- R&D Tax Incentive Review
- State Government’s Medical Technology and Pharmaceuticals Strategy
- Medical Research Future Fund (MRFF) Strategies and Priorities
- Medical Technologies and Pharmaceuticals Industry Growth Centre (MTPConnect).

Of high significance to many members is our ongoing advocacy work regarding the Federal Government’s review of the R&D Tax Incentive. We have been strong advocates on behalf of members to oppose any changes to the scheme that would hinder the sector or damage the wider health innovation ecosystem in Victoria.

In February 2016 we conducted a member-wide survey on proposed changes to the R&D tax Incentive to support our submission to the R&D Tax Incentive Review. We also used our key points for a joint submission with leading industry associations and peak bodies across Australia. The Network continues to advocate on this important policy area in a collaborative and consultative style to strengthen the industry position on the critical role the R&D Tax Incentive plays in supporting our sector.

Another focus has been our efforts around gender equity, with the Chief Executive Officer (CEO) of BioMelbourne Network invited to participate in Minister Karen Andrews’ Women in STEM and Entrepreneurship (WISE) Industry Consultation Panel.

We will continue our advocacy efforts on behalf of members in 2017 to bring member voices and views to the public policy that shapes the business environment. By representing industry views to government, we can ensure the right settings that allow members to contribute to the future of healthcare and to Melbourne and Victoria’s economic growth.
Governance and Sustainability

A highly engaged Board of Directors (the Board) is fundamental to the governance of the Network on behalf of members and we acknowledge the commitment and contribution of our volunteer directors.

10 board meetings were held during the year and the Board was supported by its two standing committees who met regularly.

The Board gave specific attention to the Network’s strategic direction. They also oversaw the financial management of the Network and the comprehensive system upgrade whilst supporting the development of our staff.

In October 2015, the Board welcomed Nigel Baade as Treasurer and Director. Nigel is a CPA-qualified accountant with extensive experience in the pharmaceutical and biotechnology industries. As the Network’s Treasurer, Nigel chaired the Finance and Audit Committee.

The Board is confident that BioMelbourne Network achieves significant outcomes and great value for money for its members through the hard work, passion and dedication of a small professional team.

BioMelbourne Network’s revenue model continues to evolve and during FY2016 the majority of income was derived from membership subscriptions, event registrations and sponsorship.

The Board acknowledged the significant contribution of retiring directors – Joe Baini, Ashley Bates and Andrew Macdonald in November 2015. Each director devoted significant time, experience and skills to the organisation and the broader sector. We extend our heartfelt thanks to Joe, Ashley and Andrew for their great work and commitment.
Networking
Delivered a record number of 49 events reaching 2,429 industry professionals, providing outstanding value to members.

The calibre of events was high, featuring 131 speakers, with 22% of events featuring international guest speakers and 31% of our speakers were women.

All of our premier events were rated as ‘excellent’ or ‘outstanding’ by 85% or more of attendees.

Advocacy
Built a strong advocacy platform through strategic government relationships, with a focus on the State Government of Victoria.

Established working groups and other channels for member consultation to inform our advocacy activities.

Made a number of individual and joint submissions to the State and Federal Governments in response to key issues and began communicating our advocacy activities through our website.

Global Connectivity
Leveraged existing and new global connections to engage with visiting VIPs, including organising a 2 day program with a US venture capital firm and hosting a delegation from Taiwan in Melbourne.

Led, together with Small Technology Cluster (STC), a high-level delegation of 18 Victorian medical technology organisations on an 8 day US Medtech Trade Mission to attend AdvaMed 2015, with site visits in San Diego and Minneapolis.

Collaboration
Developed strategic relationships with a number of peak-bodies and associated organisations (local, national and international) to expand our network and foster a connected and collaborative community where people and organisations prosper.

Used this collaborative approach to strengthen the sector’s voice in independent and joint submissions such as the R&D Tax Incentive Review.

Transformation
Implemented an intra-office digital business transformation that has decreased administrative burden and shifted our organisational focus from administration to engagement.

The overall result is a happier, smarter and more engaged work culture.

Reach
Re-designed and re-launched the BioMelbourne Network website to act as a key information portal, and to build Melbourne’s reputation as a world leading hub for health innovation. Unique visitors to the site increased by 4 fold in the first month and have been increasing ever since.

We expanded our team to include a dedicated Communications Officer.

Diversity
Championed diversity within the sector through the 8th annual Connecting Women Lunch and by expanding the BioMelbourne Network Women in Leadership Awards.

Boosted the representation of women speakers at our events and advocated for women’s participation in the broader sector.

Intelligence
The 4th annual Devices + Diagnostics Lab was held in March 2016. This event was opened by the Hon Frank McGuire MP, Parliamentary Secretary for Medical Research, featured 17 speakers and 125 attendees.

In the post-event survey 100% of attendees said they gained new insights and knowledge.

Leadership
Supported the leaders in the sector with a series of lunches addressing issues impacting decision making at a senior level.

Attendees had the opportunity to learn from and network with peers whilst being offered insights from speakers with niche expertise on a ‘hot’ topic.
Thank-You

to our community of members, supporters and friends

The power of the BioMelbourne Network resides in its members. Thank-you for all of your support in FY2016, particularly to our event host partners, sponsors, speakers and suppliers.

Thank-you to all the members who make themselves available to discuss, debate and collaborate on events and activities that impact the Network and the health innovation ecosystem in Victoria.

The funding and in-kind support from our members, partners and providers, as well as local, state and federal governments all ensure BioMelbourne Network will be sustainable into FY2017 and beyond.

Thank-you all for the role you have played in supporting the Network in FY2016 and we look forward to working for you and with you again in FY2017.

Regards,

Andrew and Krystal
Our Members

Connectivity and Sector Reach

Our Reach:

184 Member Organisations

2,194 People in Member Organisations

4,015 People in our wider network

3,575 followers on Twitter

1,218 connecting on LinkedIn
The Network is very grateful for the support and engagement of our members.

The major sponsors in the past year have been:

- Allens
- Australian Academy of Technology & Engineering (ATSE)
- Australian Red Cross Blood Service
- Australian Regenerative Medicine Institute (ARMI)
- Australian Science and Innovation Forum (ASIF)
- Australian Synchrotron
- Avatar Brokers Pty Limited
- Bioregulatory Consulting
- Brooker Consulting
- Burnet Institute
- City of Melbourne
- CSIRO Australia Animal Health Laboratory
- Csiro Manufacturing
- CSL Limited
- Davies Collison Cave
- EY
- FB Rice
- Greengage Regulatory Pty Ltd
- Griffith Hack
- Hydrix Pty Ltd
- IDT Australia Limited
- Johnson & Johnson Innovation
- Monash Institute of Medical Engineering
- Monash Institute of Pharmaceutical Sciences
- Moore Stephens (Vic) Pty Ltd
- MPR Group Pty Ltd
- Murdoch Children’s Research Institute
- Norton Rose Fulbright Australia
- Phillips Ormonde Fitzpatrick
- Piper Alderman
- PolyNovo Limited
- Starpharma Pty Ltd
- Thomson Reuters IP & Science
- Trajan Scientific and Medical
- Victorian State Government
- Walter & Eliza Hall Institute of Medical Research (WEHI)
For over 16 years BioMelbourne Network has acted as a trusted advisor and source of expertise at the nexus of government and industry.

Success for biotechnology, medical technology and pharmaceuticals is an ecosystem play, and BioMelbourne Network is committed to fostering a business environment that supports member and sector prosperity. Where members have identified issues, barriers and industry needs, BioMelbourne Network has worked to communicate concerns and represent member views at all levels of government.

Thank-you to all our members who provided detailed, powerful case studies demonstrating the issues that they face and for sharing their successes throughout the year. The Network will continue to be a champion for the sector working with local, State and Federal Governments to progress innovative industries in Victoria.

In FY2016 BioMelbourne Network has continued to promote the activity of the sector, ensuring our members’ views are heard, as well as sharing information and intelligence to build our united sector ‘voice’.

Selected highlights of our activities include:

<table>
<thead>
<tr>
<th>Profile</th>
<th>Advocacy</th>
<th>Voice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular briefings with Ministers, MPs, ministerial advisors and members of the Department of Health and the Department of Economic Development, Jobs, Transport and Resources promoting member successes and voicing member concerns.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Featured in multiple local, national and international press articles to increase Melbourne’s profile as a world leading location for biotechnology, medical technology, pharmaceuticals and health innovation.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Re-designed the BioMelbourne Network website to champion our members and profile our sector’s capabilities and achievements.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gave evidence to the Senate Economics References Committee regarding the Senate inquiry into Australia’s innovation ecosystem.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Appointed to the Minister’s Advisory Panel for the Medical Technology and Pharmaceuticals Sector Strategy working with the Victorian Government’s Department of Economic Development, Jobs, Transport and Resources.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Made an independent submission and collaborated with other industry bodies on a joint submission for the R&amp;D Tax Incentive Review in February 2016.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Submission to Medical Research Future Fund (MRFF) Advisory Board on Australian Medical Research and Innovation Five Year Strategy and Priority Areas for the MRFF.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Submission to the National Innovation and Science Agenda (NISA) on the Engagement and Impact Assessment Consultation Paper.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surveyed business members to gain additional evidence and commentary to support and inform the work of the R&amp;D Tax Incentive Review Panel.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hosted an industry roundtable lunch with the Hon Lily D’Ambrosio MP, Minister for Industry to discuss the strategies that will shape the $200 Million Future Industry Fund.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hosted an industry roundtable lunch with the Hon. Phillip Dalidakis MP, Minister for Small Business, Innovation and Trade to discuss the biotech and medtech startup ecosystem.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Clinical:Industry Working Group


The working groups created a forum for BioMelbourne Network members to discuss key sector issues, share sector intelligence, identify and respond to issues and provide input into the Network’s activities, policy positions and advocacy.

Expressions of interest in joining the groups were opened to any members of the BioMelbourne Network wishing to make a contribution, and both groups held their initial establishment meetings in February 2016.

Vision
Melbourne as a world leading location for clinical trials.

Purpose
To promote and support Melbourne as a globally competitive and attractive location for world class clinical trials.

The group met four times between February and June 2016 to share ideas and find ways to work together to further Melbourne’s clinical trial engagement and communication with industry, locally and globally.

The Clinical:Industry Working Group developed a “Melbourne Clinical Trials Attraction Plan” which was presented to representatives of the State Government (DEDJTR) outlining a program of activities to promote and attract international clinical trials to Melbourne.

The ongoing activities of the group planned for FY2017 include:

• Development of clinical trials promotional materials for international markets

• Production of a webinar aimed at the US Market to attract clinical trials to Melbourne.

“Victoria is home to highly experienced clinicians and can facilitate access to both patients and ‘trial-ready’ infrastructure.”

BioMelbourne Network would like to extend our gratitude to the members of this working group:

Judy Bingham
Executive Director, Easington Pty Ltd

Stefan Czyniewski
Principal & Clinical Affairs Director, Mobius Medical

Matt Godden
Managing Director, Australian Healthcare Solutions

Jennifer Lees
Clinical Study Manager, The Clinical Trials Company

Dr Jason Lickliter
Medical Director, Nucleus Network

Dr Megan Robertson
Director of Research, St Vincent’s Hospital (Melb) Ltd

Dr Xenia Sango
Business Development Manager, Epworth Research Institute

Dr Tina Soulis
General Manager, Neuroscience Trials Australia

Dr Dominic Wall
Chief Scientific Officer, Cell Therapies Pty Ltd
Vision
Melbourne as a city with a rich culture of collaboration that fosters industry-academic engagement.

Purpose
To identify and reduce barriers for industry-led collaboration with publicly funded research organisations, with an aim to increase collaborative R&D activity in Melbourne.

The group met four times between February and June 2016 to identify areas to work together to promote and support collaborative activity. The Industry:Academia working Group provided input into policy positions for two submissions to Federal government public consultations:

- The NISA Engagement and Impact Assessment Consultation Paper
- Medical Research Future Fund Consultation: Australian Medical Research and Innovation Five Year Strategy and Priority Areas

Thank-you to the following members of this group:

Dr Shari Lofthouse  
Head, Intellectual Property & Business Development, Peter MacCallum Cancer Centre

Assoc. Prof. Michelle McIntosh  
Pharmaceutical Scientist, Monash Institute of Pharmaceutical Sciences

Dr Tim Oldham  
Chief Executive Officer, Cell Therapies Pty Ltd

Dr Jeanette Pritchard  
Chief Operating Officer, Monash Vision Group

Dr David Rhodes  
Chief Scientific Officer, Admedus Ltd

Dr Mark Sullivan  
Chief Executive Officer, Medicines Development Ltd

Dr Amabel Tan  
Life Sciences Solutions Consultant, Thomson Reuters IP & Science

Angela Tomisich  
Director, Trajan Scientific and Medical

Dr Paul Wood  
Executive Officer, IMNIS (Industry Mentoring Network in STEM)

Dr Elane Zelcer  
Director, BioConsult Pty Ltd
International Connectivity & Engagement

Collaborations and partnerships drive innovation and both local and international connections are critical for the growth of the sector here in Melbourne.

A priority area for BioMelbourne Network is to build the international reputation of Melbourne’s biotechnology, medical technology and pharmaceutical sector. Our goal is to create relationships that help our members “go global”, especially growth-stage and commercial companies who are exploring access to international markets.

A growing role for the Network is acting as a ‘concierge’ service for international companies wanting to do business in Melbourne, helping them connect with the partners they are looking for. We hosted business-to-business meeting sessions with key strategic partners, made dozens of facilitated introductions to members and arranged site visits for international guests to showcase Victoria’s capabilities.

Our event program provides international guests with opportunities to share their insights which ensures members are kept up-to-date on global industry trends and have informed strategies for engaging with the international markets.

In FY2016 we hosted 15 international speakers at our events, including:

- **Tom Heyman**
  Global Head of Business Development, Pharmaceuticals Group of Janssen Global Services, LLC

- **Dr Thomas Lönngren**
  former Executive Director of the European Medicines Agency

- **Eric B. Cheng**
  Senior Managing Director, Head of Healthcare Investment Banking, Maxim Group LLC

- **Ronnie Farquhar**
  Entrepreneur in Residence, Morningside Ventures

- **Dr Martha J. Morrell**
  Clinical Professor of Neurology at Stanford University

- **Dr. Timothy Coté**
  Principal and CEO at Coté Orphan and Former Director of the FDA Office of Orphan Products Development (OOP)

- **Kenneth Morris**
  Founder, KnectIQ Inc.

- **Tzou-Yien Lin**
  Deputy Minister of Ministry of Health and Welfare of Taiwan

- **Anita Chien**
  Consultant, Nomura Research Institute Taiwan

- **Dr David Reddy**
  CEO of Medicines for Malaria Venture
BioMelbourne Network

AdvaMed 2015
Melbourne medtech going global

Victorian Medtech Mission to the US: AdvaMed 2015

BioMelbourne Network and STC Australia, on behalf of the State Government of Victoria, led a delegation of 18 Victorian companies on an 8-day Medtech Trade Mission to the US in October 2015.

The mission itinerary included a visit to San Diego and attending AdvaMed 2015, the leading medtech conference in the US. The Victorian Medtech Trade Mission was the largest international delegation at AdvaMed 2015 and with a prominent exhibition booth in the Trade Hall, the delegation boosted the profile and international awareness of the growing, dynamic medical technology cluster here in Melbourne.

Delegates also visited Minneapolis in Minnesota, a global medtech hub, for a 2-day program designed to build trade, investment and partnering relationships with networking and business matching activities facilitated by hosts, Life Sciences Alley and Greater MSP.

Over the 8-day trade mission, the delegates held 200 significant meetings with high quality business leads including investors, corporate strategic partners, research collaborations, clients and commercialisation specialists. The impact of these connections is expected sales and capital investments to the value of $10.5 million over the next 12-36 months for delegate companies, representing an excellent return for trade and investment opportunities for Victoria.

The Medtech Trade Mission delegation returned to Victoria with increased knowledge and skills, improved commercial connections in US and opportunities for sales, export, licensing, new business revenue and investment. The mission also enhanced the connectivity between delegates, identifying areas of collaboration and partnership between delegation companies, contributing to a connected, networked local medtech ecosystem here in Victoria.

When surveyed, 100% of mission delegates reported that the Mission gave them a deeper understanding of the US market.

Trade and Investment Outcomes

• Start-up medtech company exploring a partnership opportunity with a major multinational medical device company
• Early stage company now in discussion with international venture capital regarding investment opportunity
• Collaborative partnership negotiations to bid for contract research opportunity with a European healthtech ecosystem research project
• Manufacturing, engineering and design supplier engagement to provide R&D services to new international clients
• Expanding existing trade and supply with US clients for supply of R&D services

San Diego

AdvaMed conference highlights included:

• International Seminar – Focussing on US market access
• Entrepreneur BootCamp – For start-ups and early stage growth companies
• Medical device development workshop

Minneapolis

"Minnesota Meets Melbourne MedTech" networking event hosted by Life Science Alley and Greater MSP (Minneapolis Saint Paul Regional Economic Development Partnership)

"Partnering with Corporate Strategics" panel session and Q&A session with perspectives from current and former executives from:

• Boston Scientific
• 3M
• Medtronic

Site Visits:

• SunShine Heart – A medical technology company focussed on heart failure, originally founded in Melbourne, now headquartered in Minneapolis
• Smith’s Medical - A leading multinational manufacturer of specialty medical devices and consumables, with global headquarters in St. Paul, Minnesota.

“I found it really useful to be able to get face-to-face with people that may usually be difficult to access - i.e. senior executives. Most were engaging and insightful which was encouraging and inspiring.”
As a geographic gateway to the Asia-Pacific region, Taiwan is ideal to springboard into the mainland Chinese market. To highlight increasing opportunities for engagement in the region, BioMelbourne Network hosted a delegation from Taiwan in Melbourne in September 2015.

The high-level delegation included Tzou-Yien Lin, Deputy Minister from Taiwan’s Ministry of Health and Welfare, who spoke with members at a special seminar event, as well as participating in B2B meetings, informal networking and tours of Melbourne’s new and well-established healthcare innovation infrastructure.

The Taiwanese government has launched successive waves of plans, policies, funding and reforms over the last two decades culminating in a transformation of its life science sector. The combined market capitalization for Taiwanese life science companies increased from US$3 billion to US$30 billion over five years, with a booming biotechnology industry supported by strong government funding and private sector interest. Anti-cancer, anti-aging, tissue culture, herbal medicine, medical devices, bio-chip and informatics are the hot topics in healthcare innovation in Taiwan.

BioMelbourne Network facilitated a series of custom matched business meetings to assist the delegates in their search for products and technology to develop new drugs and devices in these areas.

Hosting the Taiwanese Trade Mission enabled BioMelbourne Network members to profile their company to the Ministry of Health and Welfare, and outline their capabilities for partnering and investment opportunities in Taiwan. The networking sessions allowed for the further exchange of knowledge and provided insights into the business priorities in Taiwan for long-term growth and success.
Our Events

The high calibre event program over the year provided a range of events to serve the diversity of interests throughout the membership and provide premier networking opportunities. Our events featured meetings, roundtable lunch discussions, workshops, informative breakfasts and briefings and manufacturing facility tours with a number of overseas speakers including from Europe, Taiwan and the US.
BioMelbourne Network held its 4th annual Devices + Diagnostics Lab on the 17th of March, 2016 with the theme “Wireless and Wearable Technology”.

Wireless and wearable devices are the fastest moving frontier in medical technology. The medical wearables market, excluding wellness and fitness, is expected to grow by 65%, hitting $6 billion in 2016.

The ability to track, monitor and analyse a person’s health metrics creates unique clinical and business opportunities.

After the official welcome and opening speech by the Hon Frank McGuire MP, Parliamentary Secretary for Medical Research, the 125 attendees of this full day event heard from 17 speakers around 6 key themes:

• Disruption and opportunity in global markets
• Connected and data-driven healthcare
• Future Trends: Where to next for wearables?
• Company Q&A – the devil is in the detail
• Strategies for regulation and reimbursement
• Raising capital and doing deals.

BioMelbourne Network extends thanks to our program advisors, Paul Clark and Tom Stamp for their outstanding contributions to curating the sessions and speaker line-up.

• 100% of attendees said they gained new insights and knowledge
• 90% thought the event was either excellent or outstanding.

“Absolutely fascinating wearable medical device seminar in Melbourne last week, I was amazed to see Australia was a leader in the area. The speakers were of an incredibly high standard and thanks to all for sharing so freely. Great event BioMelbourne Network, well done!”
For smaller biotech and medtech companies knowing how and when to engage with larger strategic partners can make the difference between success and failure.

The Partnering Forum is an annual fixture of BioMelbourne Network’s event calendar bringing together the health innovation ecosystem of Melbourne to discuss new approaches to partnering and collaboration.

At the November 2015 Partnering Forum 55 attendees heard from 10 speakers, including representatives from Johnson & Johnson Asia Pacific Innovation Centre, Pfizer, Admedus, APAC Health and GBS Venture Partners.

Speakers shared insights into their company’s approach to strategic partnerships and alliances, providing real-world examples of when and how to engage with larger multi-nationals.

Overall this event Partnering Forum provided key information on positioning for global engagement, promoted local case studies and illuminated the pathways to partnership for product development.

With 85% of attendees rating the event as “excellent”, many of the audience are now thinking differently about approaches to their partnering strategy and their business model. Networking was also a key part of the day, with two-thirds of attendees making a new business contact to follow up on.

“…a brilliant session on licensing and collaboration this morning! I loved it: very high calibre presenters, I learnt a lot and it was brilliant for making new connections as well as catching up with old friends.”
BioMelbourne Network recognises that innovation is a people-driven process that thrives on diverse thinking and views. To build a strong, resilient and successful innovation ecosystem, Australia needs to harness the talents of both men and women.

Although the biotechnology, medical technology and pharmaceutical sector is powered by women, who make up the majority of the workforce, they are under-represented in senior leadership roles.

A flagship event for the Network is the Connecting Women Lunch and this year we held our 8th annual gathering on the 20th of May 2016.

This event is a key opportunity for women across the life sciences industry to extend their professional networks, establish mentoring relationships and to share their experiences over lunch. In 2016 the lunch sold out within 2 weeks of tickets going on sale resulting in just over 410 attendees including senior representatives from industry, government and academia.

As with previous years, CSL presented an entertaining video clip around a theme which this year was taken from their centenary celebrations “100 Years Old and Just Getting Started!” The “just getting started” theme carried through to the popular “On the Couch with Dr Krystal” interview session with three guests who shared candid experiences and advice:

**Shelly Park**
Chief Executive Officer, Australian Red Cross Blood Service

**Dr Megan Baldwin**
Managing Director & Chief Executive Officer, Opthea Ltd

**Dr Lorna Meldrum**
VP Commercial Operations Asia/Pacific, Seqirus

This year our chosen charity partner was SisterWorks – a social enterprise here in Melbourne that empowers asylum seeker, refugee and migrant women to bring financial independence and entrepreneurship into their own lives. The donations totalled a much-needed $9,506. Thank you to our attendees for their generosity.

Social media was abuzz on the day, sharing this celebration of diversity with a wider online audience. The twitter hashtag #biomelbwomen was used in 642 tweets and made over 1.3 million impressions.
Women in Leadership Awards

BioMelbourne Network Women in Leadership Awards champion rising stars and outstanding leaders in biotechnology, medical technology and pharmaceuticals who are driving the future of healthcare innovation.

Since their inception in 2015, the awards have gone from strength to strength. The calibre of the applications that we received was phenomenal and it was both inspiring and humbling to have the outstanding achievements of women in the sector highlighted.

The selection panel for the awards consisted of members of the BioMelbourne Network Board - Maureen O’Keefe, Alun Needham, Andrew Carter and Dr Lorna Meldrum, with the 2015 ‘Women in Leadership’ awardee Dr Elaine Saunders. All of the panel members commented on what a difficult process it was to select winners.

The 2016 BioMelbourne Network Women in Leadership Awards were presented by the Honourable Linda Dessau AM, Governor of Victoria at the Connecting Women Lunch.

There were 3 awards presented:

**Women in Leadership**
Recognises senior corporate leadership and directorship

**Winner:** Dr Jackie Fairley, Starpharma Pty Ltd

**Most Valuable Women in Leadership**
Celebrates leadership of teams, projects and initiatives

**Winner:** Prof. Sally McArthur, Swinburne University of Technology

**Emerging Women in Leadership**
Acknowledges rising stars with high potential for future success

**Winner:** Jacqueline Savage, MedCorp Technologies

Thank you to all of those members who took the time to nominate one of the many talented women in the sector for these awards. And to those of you who are continuing to champion and celebrate the achievements of women in the sector, it’s a powerful way to increase the representation of women in leadership roles.

It was fantastic to see a number of applications from people nominating someone from outside their own organisation. This really speaks to the collaborative and connected community we have here in Melbourne.

“I must say I found this an incredibly challenging exercise given the fantastic nominees, range of experiences and achievements and diverse roles and backgrounds. It just shows the calibre of the female component of the local life sciences community.”

2016 Selection Panel
Supporting Sector Leaders

The BioMelbourne Network event program is designed to support leaders at all levels within our member organisations. We run a series of events specifically designed for Non-Executive Directors, CEOs, CFOs and senior management team members, supporting them to achieve global competitiveness.

14 leadership events were run in FY2016 incorporating workshops, presentations and round-table discussions.

Highlights included:

**July 2015**
CEO Breakfast with international guest speaker Eric B. Cheng, Senior Managing Director, Head of Healthcare Investment Banking, Maxim Group LLC.

**September 2015**
Leadership Roundtable Lunch with the Hon Lily D’Ambrosio MP, Minister for Industry, Energy and Resources with guests reflecting on the themes emerging from the consultations on the development of the Victorian Medical Technologies and Pharmaceuticals Sector Strategy as well as strategies that will inform the investment of the $200 Million Future Industry Fund.

**September 2015**
End of Financial Year Reporting and Season Wrap-up. Non-Executive Director Lunch addressing common themes and issues arising out of FY2015 year-end reporting. Emerging thoughts on how to ‘streamline’ corporate communication and messaging to investors and stakeholders in advance of the forthcoming AGM season were also discussed.

**October 2015**
Leadership Roundtable Lunch with international guest Rick Robinson, Global Co-Head of Life Sciences, Norton Rose Fulbright discussing Medical Device Regulatory Challenges for the FDA.

**November 2015**
Tax Risk Management Non-Executive Director Lunch considering Board actions required to ensure there is an effective tax risk management framework in place.

**February 2016**
Leadership Lunch at FB Rice with international guest Ronnie Farquhar, Morningside Ventures (Boston, USA) speaking about Approaches to Building & Supporting Innovative Biotech.

**May 2016**
CFO Post- Budget Lunch at EY with guest speaker Mr Nigel Baade, CFO of Starpharma who discussed a range of finance challenges and strategies using recent Starpharma milestones as case study examples.

**May 2016**
Executive and Board Remuneration. Non-Executive Director Lunch providing the opportunity to consider key issues and anticipated trends in executive and board remuneration. Insights were supported by an analysis of quantum and policy information for the 100 largest companies in the S&P/ASX200 Index as well as trends observed for private/unlisted companies.

**June 2016**
Leadership Roundtable Lunch with the Hon Phillip Dalidakis MP, Minister for Small Business, Innovation and Trade. This roundtable provided the opportunity to lead the discussion on the policy settings needed to support new venture creation in Victoria and identify where government programs can be of most value to the biotech and medtech startup community.

“An interesting opportunity to hear from a diverse group of stakeholders and gain an appreciation of recent government initiatives to support the life sciences sector.”
In FY2016 several of our members have opened their doors and hosted events and facility tours for BioMelbourne Network members. Victoria’s R&D infrastructure is world class, however many companies are unaware of the extent of the opportunities and resources that exist in their own ‘backyard’.

BioMelbourne Network assists companies to stay abreast of the available technologies, equipping them with knowledge on how to access local R&D infrastructure and expertise, and to learn from experienced manufacturers by showcasing Melbourne’s world leading facilities.

The Australian Red Cross Blood Service hosted the BioBriefing -

*Lean in the Blood Service and Facility Tour, September 2015*

Having won the 2012 Master Builders and Environmental Design Awards, the facility tour showcased the state-of-the-art processing facility in West Melbourne that is responsible for processing 40% of Australia’s blood supply. This event provided an understanding of how the Blood service are applying ‘lean’ manufacturing principles to including visual management tools and user-design workshops to improve quality and productivity outcomes. This forum provided a great opportunity for members to share experiences and to learn from colleagues on best practise for medical manufacturing.

The Australian Synchrotron hosted the BioBriefing -

*Seeing is Believing - Advances in Imaging Technology R&D, October 2015*

Members heard from scientists from 2 of the Melbourne-based ARC Centres of Excellence who are exploring next-generation imaging technologies. The presentations prompted an exciting discussion about how advances in synchrotron science and imaging techniques provide powerful tools for pre-clinical development and enhance early-stage R&D decision-making. Members were then able to tour this world-class facility, a rare “up close” view of the beamlines and operations at the Australian Synchrotron.

Geelong’s CSIRO Australian Animal Health Laboratory hosted the BioBreakfast -

*Biocontainment Capability for Biotech, June 2016*

Members attending the briefing also had a virtual tour of the high-containment facility which enables research on high-consequence, dangerous pathogens such as Ebola and influenza, and offers unique pre-clinical testing capability. With the increased global threat from emerging infectious diseases and pandemics, Victoria is well positioned to be a leading global hub in this critical area of unmet need. This event highlighted the unique capabilities that support research and product development for emerging infectious diseases.
Medical Manufacturing

In FY2016 BioMelbourne Network held two events with included on-site tours of leading medical manufacturing facilities.

Advanced manufacturing needs advanced products, and with Victoria’s strong innovation and IP base, medical manufacturing is transitioning our economy toward a high-tech, specialised, high-value, smart future.

Trajan Scientific and Medical

In October 2015, Trajan Scientific and Medical hosted the BioBriefing “Quality Initiatives - Transformation and Training for Building Business Value” which included a tour of their Ringwood facilities.

Trajan Scientific and Medical collaborates with academic and industry partners to develop and deliver innovative products that will improve human wellbeing through biological, environmental or food related measurements.

The 17,000 m2 Ringwood site in Melbourne, Victoria, is home to Trajan’s corporate headquarters and ISO accredited manufacturing operations. With over 300 staff worldwide across Australia, Europe, USA and Asia, Trajan serves customers in over 100 countries with highly specialised consumables and components used in scientific analysis and clinical applications.

PolyNovo Limited

Paul Brennan, CEO PolyNovo shared his experiences of leading an ASX listed company at a BioMelbourne Network Leadership Lunch in June 2016. Guests also enjoyed a tour of the PolyNovo advanced manufacturing facility in Port Melbourne, where their biodegradable medical devices are produced.

PolyNovo is a Melbourne-based medical device company that designs, develops and manufactures solutions for standalone and combination devices using its NovoSorb™ biodegradable polymer technology.

PolyNovo’s current focus is on the development and commercialisation of innovative medical devices using its NovoSorb™ technology in the treatment of burns, surgical wounds and Negative Pressure Wound Therapy.
Melbourne
leading the way in biotechnology, medical technology and pharmaceuticals

Melbourne is the city that anchors Australia’s healthcare innovation ecosystem

1/3 of Australian clinical trials activity takes place in Victoria

40% of companies and 60% of Australia’s market capitalisation for biotechnology, medical technology & pharmaceuticals resides in Melbourne

Melbourne is one of only three cities in the world to have two universities in the global top 20 biomedicine rankings

Victoria’s biotech, medtech and pharma sector collectively employs over 21,000 people & 20,000 researchers

Melbourne attracts more than 40% of Australia’s medical research funding

Melbourne is home to more than 22 pharmaceutical manufacturers

Melbourne is a collaborative city! Ranked in GLOBAL 10 CITIES for most intra-city research partnerships
Our Goals

“Melbourne’s biotechnology, pharmaceutical and medical technology companies are competing successfully in international markets, cementing the city’s reputation as a vibrant destination for global biotechnology companies and a low risk, high quality and competitive business environment, and a gateway to Asia.”

Andrew Wear
Director Medical Technologies and Pharmaceuticals Sector, State Government of Victoria

Run awesome events
Deliver a strong event program with high calibre speakers that informs members on industry trends and creates valuable networking opportunities.

Strengthen the network
Enhance the reach of the BioMelbourne Network within our member organisations, and across the health innovation sector in Melbourne.

Be an influential leader
Build BioMelbourne Network’s profile as the leading advocate for health innovation in Victoria by acting on member concerns and providing opportunities for members to voice their views on issues.

Increase connectivity
Increase local, national and global connectivity, promoting the activities of our members and encouraging collaboration to advance strategic goals.

Profile raising
Promote the sector with a high quality brand and profile Melbourne’s potential as a world-leading R&D hub.

Work smarter and happier
Increase BioMelbourne Network’s operational efficiency and sustainability to better serve member needs.
Your Network

Connect at an event
Make new business contacts, catch up with colleagues and meet with industry leaders. Attendee lists are sent out to members prior to the event to let you know who to look out for.

Host an event
Partnering with the BioMelbourne Network to deliver events increases your visibility in the sector and demonstrates your support and commitment to the local industry.

Let us introduce you
We make hundreds of personal, facilitated introductions every year, connecting members who are in search of suppliers, talent, partners, consultants and investors. Make our network your network in 2017.

Voice your concerns
If your business has run into a barrier, the chances are you aren’t the only one struggling with the issue. We participate in government submissions, industry consultations and respond to member-specific issues as a trusted and respected voice for the sector.
Your issues are our issues.

Share your story
The more we know about your business strategy and direction for 2017, the more we can assist with your needs and further your goals. We held over 80 one-on-one member engagement meetings in FY2016, and this close consultation with members directs our activities.

Suggest a speaker or topic
Our events are customised to the needs and interests of members, and our flexibility means we take requests. If you have an international visitor in town for a few days, want share business best practise, or think there’s a hot button issue that we all need to talk about, let us know.
Our Members

10+ Years

Acrux Ltd
Advent Pharmaceuticals Pty Ltd
Agriculture Victoria Services Pty Ltd
AusBiotech Ltd
Australian Genome Research Facility
Avatar Brokers Pty Ltd
Avexa Ltd
Bio21 Molecular Science & Biotechnology Institute
BioConsult Pty Ltd
Biomedical Research Victoria
Bioregulatory Consulting
BioShares
Brooker Consulting
Burnet Institute
Cell Therapies Pty Ltd
City of Melbourne
Committee for Melbourne
CSIRO Manufacturing
CSL Ltd
Davies Collison Cave
EY
FB Rice
Freehills Patent Attorneys
Genetic Technologies Ltd
Griffith Hack
Hudson Institute of Medical Research
Melbourne Health
Minter Ellison
Monash University
Murdoch Children’s Research Institute
Neurosciences Victoria
Norton Rose Fulbright Australia
Nucleus Network
Phillips Ormonde Fitzpatrick
PwC
Science in Public
St Vincent’s Institute of Medical Research
Starpharma Pty Ltd
Thomson Reuters IP & Science
Walter and Eliza Hall Institute of Medical Research
Watermark Patent & Trade Mark Attorneys
5+ Years

Admedus Ltd
Afandin Pty Ltd
Alex Ascenzo
Antisense Therapeutics Ltd
ARCS Australia Ltd
Australian Red Cross Blood Service
Australian Regenerative Medicine Institute
Australian Synchrotron
Axxin
Bio Actives Exports Pty Ltd
BioDetectors Pty Ltd
Bio-Link Australia Pty Ltd
Blamey Saunders Hears
Brandon Capital Partners
Cancer Trials Australia
Chubb Insurance Company of Aust. Ltd
CTx CRC Ltd
Deakin Research - Commercial
Deloitte
Department of Economic Development
Easington Pty Ltd
ERA Consulting Australia
Gilead Sciences Pty Ltd
Global Kinetics Corporation
Hydrix Pty Ltd
IDT Australia Ltd
Immuron Ltd
INC Research Australia Pty Ltd
Janssen-Cilag Pty Ltd
LBT Innovations Ltd
Mallinckrodt Pharmaceuticals
Medical Developments International
Medicines Development Ltd
Merck Sharp & Dohme Australia
Mesoblast Ltd
Moore Stephens (Vic) Pty Ltd
Neuroscience Trials Australia
Opthea Ltd
Otifex Therapeutics Pty Ltd
Paranta Biosciences
Pfizer Australia Pty Ltd
Phosphagenics Ltd
Piper Alderman
Planet Innovation
PolyActiva
Prana Biotechnology Ltd
Quintiles Pty Ltd
Reblan Pty Ltd
Research Australia
Science Industry Australia Inc
ScribblersInc
Sienna Cancer Diagnostic Ltd
Stella Connect Pty Ltd
Traders Macquarie Pty Ltd
Universal Biosensors Pty Ltd
VLSCI
Wild Child Cosmeceuticals

2+ Years

affinity bio
Alexander Gosling
Arrayware Pty Ltd
Ashley Bates Consulting
Australian College of Optometry/National Vision Research Institute
Bank of Melbourne
Bionics Institute
Centre for Eye Research Australia
d3 Medicine LLC
Design + Industry
Epworth Research Institute
eXec Factor Pty Ltd
Gordagen Pharmaceuticals Pty Ltd
Grey Innovation
Hatchtech
Illumina Australia Pty Ltd
Marilyn Careers
MMV (Medicines for Malaria Venture)
MPR Group Pty Ltd
Orius Pty Ltd
Outerspace Design Group
Patheon Biologics Australia Pty Ltd
Specialised Therapeutics Australia
Trajan Scientific and Medical
The CFO Solution
VCAMM (Victorian Centre for Advanced Materials Manufacturing)
World Courier (Australia) Pty Ltd
Recent Members

4Dx Pty Ltd
Adalta Pty Ltd
Agilent Technologies
Allens
AquaTrophic Pty Ltd
Aus Bio Ltd
Australian Healthcare Solutions
Blue Curve
Centre for BioPharmaceutical Excellence
CNSDose
Commercial Eyes
Computer Frameworks
Department of Human Services
Dimerix Ltd
EBC Consulting Pty Ltd
Fire Films
GeneMiner
Greengage Regulatory Pty Ltd
Haplonic Technologies Pty Ltd
Health&
ImmuPharma plc
Kesem Health
La Trobe - College of SHE
MedCorp Technologies
Medtasker (Nimblic)
MiniFAB (Aust) Pty Ltd
Mobius Medical
Molecule2Market Pty Ltd
Neuren Pharmaceuticals Ltd
Noxopharm Ltd
nuraloop
Ondek Pty Ltd
Patrys Ltd
Peter MacCallum Cancer Centre
PolyNovo Ltd
Prima Biomed Ltd
Raven Consulting Group
Ribosomal Pty Ltd
SeerPharma Pty Ltd
Sementis Ltd
SmartStent Pty Ltd
Sonic Clinical Trials Pty Ltd
St Vincent’s Hospital (Melb) Ltd
Statistical Revelations Pty Ltd
Swinburne University of Technology
Swisse Wellness Pty Ltd
Technovalia Pty Ltd
TetraQ Research Infrastructure
The Clinical Trial Company
The Peter Doherty Institute for Infection and Immunity
The Royal Society of Victoria
UK Department for International Trade
University of Melbourne (RIC)
Victorian Cancer Biobank
ViraLytics Ltd

Life Members

Dr John Raff
Mr Tim Murphy
Dr Janine Kirk AM
Prof. David de Kretser AC
Our Events

Premier Events

27 . 11 . 15
Health Technology Partnering Forum ‘Collaborate to Innovate: Approaches to Partnering’ - Piper Alderman

17 . 03 . 16
Devices + Diagnostics Lab - Wireless & Wearable Technology - sponsored by the State Government of Victoria

20 . 05 . 16
Connecting Women Lunch 2016

BioBreakfasts

07 . 07 . 15
Think Global: Strategies for International Positioning’

06 . 08 . 15
Innovation in Epilepsy at the Interface of Industry and Research' The Melbourne Brain Centre

30 . 11 . 15
Innovation Week Launch Breakfast’ - Australian Science & Innovation Forum (ASIF) & Academy of Technological Sciences & Engineering (ATSE)

23 . 02 . 16
Reshaping the landscape for investing in innovation'

14 . 04 . 16
Scaling-up for success: Production, and manufacturing for commercial product development’ - CSIRO
## BioBriefings

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>01.07.15</td>
<td>‘Partnerships and pathways for product development and impact in tropical medicine’</td>
<td>The Burnet Institute</td>
</tr>
<tr>
<td>09.07.15</td>
<td>‘Hype or reality? Applied data transforming health’</td>
<td>Murdoch Childrens Research Institute</td>
</tr>
<tr>
<td>30.07.15</td>
<td>MedTech Mission to US including AdvaMed Conference 2015</td>
<td>State Government of Victoria</td>
</tr>
<tr>
<td>18.08.15</td>
<td>The JP Morgan Annual Healthcare Conference Experience</td>
<td>Nexia Australia</td>
</tr>
<tr>
<td>04.09.15</td>
<td>“Investment and partnering opportunities in Taiwan: The business and healthcare industry landscape”</td>
<td>The Ministry of Health and Welfare, Taiwan</td>
</tr>
<tr>
<td>17.09.15</td>
<td>‘Lean in the Blood Service’ &amp; Facility Tour</td>
<td>Australian Red Cross Blood Service</td>
</tr>
<tr>
<td>23.09.15</td>
<td>Why Hack?</td>
<td>Open Knowledge Foundation and Carlton Connect Initiative</td>
</tr>
<tr>
<td>29.09.15</td>
<td>MedTech Mission to US including AdvaMed Conference 2015 Pre-Departure Briefing</td>
<td>State Government of Victoria</td>
</tr>
<tr>
<td>20.10.15</td>
<td>Quality Initiatives; Transformation and Training for Building Business Value’ &amp; Facility Tour</td>
<td>Trajan</td>
</tr>
<tr>
<td>26.10.15</td>
<td>Seeing is believing: Advances in imaging technology R&amp;D’ &amp; facility tour</td>
<td>Australian Synchrotron</td>
</tr>
<tr>
<td>28.01.16</td>
<td>Hot or Not: Trends for 2016’</td>
<td>Philips Ormonde Fitzpatrick</td>
</tr>
<tr>
<td>16.02.16</td>
<td>Innovation with Impact: Unrecognised Opportunities in Global Health’</td>
<td>WEHI</td>
</tr>
<tr>
<td>03.03.16</td>
<td>The AusIndustry Entrepreneurs’ Programme</td>
<td>Moore Stephens</td>
</tr>
<tr>
<td>22.03.16</td>
<td>Establishing the Medical Countermeasures Incubator Program’</td>
<td>Defence Materials Technology Centre &amp; the Monash Institute of Pharmaceutical Science</td>
</tr>
<tr>
<td>28.04.16</td>
<td>Advances in 3D Printed Biomedical Devices’</td>
<td>Monash Institute of Medical Engineering</td>
</tr>
<tr>
<td>21.06.16</td>
<td>Biocontainment capability for Biotech’ &amp; virtual tour</td>
<td>CSIRO Australian Animal Health Laboratory</td>
</tr>
</tbody>
</table>

## B2B Sessions

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>02.12.15</td>
<td>Regulatory Consulting Triage, Drop-in sessions</td>
<td>Greengage Regulatory</td>
</tr>
<tr>
<td>08.03.16</td>
<td>Entrepreneurs Program Drop-in sessions</td>
<td>AusIndustry</td>
</tr>
<tr>
<td>31.03.16</td>
<td>Devices + Diagnostics Lab - Post workshop drop-in sessions</td>
<td></td>
</tr>
<tr>
<td>19.04.16</td>
<td>Regulatory Consulting Clinic Drop-in Sessions</td>
<td>Bioregulatory Consulting</td>
</tr>
</tbody>
</table>

## Industry Consultations

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>03.09.15</td>
<td>‘In Conversation with Thomas Lönngren: An Intimate EU-Global Regulatory Workshop’</td>
<td>PwC</td>
</tr>
<tr>
<td>01.10.15</td>
<td>Regulatory Workshop: Orphan Drug Development and Registration</td>
<td></td>
</tr>
</tbody>
</table>
Leadership Lunches

23 . 07 . 15
CEO Breakfast with Eric B. Cheng, Senior Managing Director, Head of Healthcare Investment Banking, Maxim Group LLC - Davies Collison Cave

29 . 07 . 15
'The Regenerative Medicine Industry Interface Program' with Mr Silvio Tiziani, COO - Australian Regenerative Medicine Institute & Monash University

21 . 08 . 15
Roundtable Lunch With Tom Heyman, President, Johnson & Johnson Development Corporation - FB Rice

10 . 09 . 15
Roundtable Lunch with the Hon Lily D’Ambrosio MP, Minister for Industry & Minister for Energy and Resources - Allen’s

16 . 09 . 15
Non-Executive Directors Luncheon Series ‘End of Financial Year and Reporting Season Wrap-up’ with Mr Ken Weldin - EY

22 . 10 . 15
Roundtable Lunch with Tim Heberden, IP Valuation Director, ‘Rationalising your IP Portfolio & Generating Value from Underutilised IP’ - Griffith Hack

23 . 10 . 15
Leadership Roundtable Lunch with Rick Robinson, Global Co-Head of Life Sciences and Healthcare ‘Medical Device Regulatory Challenges for the FDA’ - Norton Rose Fulbright

06 . 11 . 15
Leadership Lunch on ‘Innovation and Entrepreneurship’ with Frank McGuire, Parliamentary Secretary for Medical Research - Norton Rose Fulbright

20 . 11 . 15
Non-Executive Directors Lunch Series ‘Tax Risk Management’ with Ms Sue Williamson - EY

15 . 02 . 16
Morningside Ventures ‘Approach to Building & Supporting Innovative Biotech’ with Ronnie Farquhar, Morningside Ventures (Boston, USA)

12 . 04 . 16
R&D Tax Incentive Workshop & Lunch with Mr Brendan Brown and Ms Simone Quinn- MPR Group

13 . 05 . 16
Non-Executive Directors Luncheon Series ‘Executive and Board Remuneration -what does the future look like?’ with Mr Andrew Webster - EY

31 . 05 . 16
CFO Post- Budget Lunch with Mr Nigel Baade, Starpharma and Mr Andrew Cowlishaw - EY

15 . 06 . 16
Facility Tour and CEO Lunch with Mr Paul Brennan, CEO, PolyNovo - PolyNovo

Social Function

10 . 12 . 15
BioMelbourne Network & AusBiotech’s Christmas Function 2015